Drug Trial Radar · NCT03505853
A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)
Last checked: Nov 20, 2026Latest source record: Mar 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Apr 26, 2018
Primary completion
Nov 16, 2018
Study completion Jan 10, 2019
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Apr 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of givosiran on the pharmacokinetics of the 5-probe cocktail of midazolam, caffeine, losartan, omeprazole, and dextromethorphan, and their metabolites, in asymptomatic patients with Acute Intermittent Porphyria.
Conditions
- Acute Intermittent Porphyria (AIP)
- Acute Hepatic Porphyria (AHP)
- Porphyria, Acute Intermittent
- Acute Porphyria
Interventions
GivosiranDrug
single dose of givosiran by subcutaneous (sc) injection
5-probe cocktailDrug
includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktailTime frame: Days 1 and 36
- Profile of Pharmacokinetics (PK) of Cytochrome P450 (CYP) probe cocktailTime frame: Days 1 and 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.